Trajan Group Holdings (ASX:TRJ) has entered into an agreement to acquire all aspects of Sierra Analytics’ HDExaminer software business through its US-based subsidiary.
The company says it aims to acquire all aspects of Sierra’s HDExaminer software business for US$430,000.
Adding on, Trajan notes that HDExaminer is used in Hydrogen Exchange Mass Spectrometry (HDX-MS), which represents a powerful technique providing insight into protein dynamics. Studies on HDX-MS can be used to connect structure, behaviour, and function of protein, between proteins and drugs, development of life-saving vaccines, as well as cause the potential resolution of protein misfolding diseases.
“Bringing ownership of HDExaminer into the Trajan family allows us to invest in the future development and enhancement of this powerful analytical platform”
Trajan also notes HDExaminer revenues were about US$350,000 in the financial year 2022, of which Trajan retained 35% as the exclusive distributor.
Commenting on the agreement, Trajan Group Holdings CEO Stephen Tomisich said: “Bringing ownership of HDExaminer into the Trajan family allows us to invest in the future development and enhancement of this powerful analytical platform.
Together with our growing number of leading collaborations in the field of HDX-MS we expect to target several areas of the package to enable broader adoption of the technique along with enhancing the depth and value of protein structural information that can be revealed.”
Trajan Group Holdings is an ASX-listed company that represents a global leader in the automation of the HDX-MS technique, being an exclusive distributor of the HDExaminer since early 2018. The company is also a leading global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement.
The company’s products and solutions are utilised in the analysis of biological, food, and environment samples. In addition, Trajan currently boasts a portfolio and pipeline of new technologies which support the move towards decentralised and personalised data-based healthcare.
Trajan is a global organisation with more than 680 people, with 7 manufacturing sites across the US, Australia, Europe, and Malaysia, and operations within Australia, the US, Asia, and Europe.